Neurotech International Ltd (ASX:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18

Recommended

Our coverage remains overvalued.

Jon Mills, CFA | 14 January 2026

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

William Kerwin, CFA | 12 January 2026

The shares are overvalued as investors are overly excited about defence and gold exposure.

Esther Holloway | 12 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,151.80	0.10	0.00%
CAC 40	8,347.94	0.74	0.01%
DAX 40	25,333.38	87.28	-0.34%
Dow JONES (US)	49,191.99	398.21	-0.80%
FTSE 100	10,174.99	37.64	0.37%
HKSE	26,999.81	151.34	0.56%
NASDAQ	23,709.87	24.03	-0.10%
Nikkei 225	54,341.23	792.07	1.48%
NZX 50 Index	13,757.71	101.66	0.74%
S&P 500	6,963.74	13.53	-0.19%
S&P/ASX 200	8,820.60	1.20	-0.01%
SSE Composite Index	4,126.09	12.67	-0.31%